CalSTRS Loads Up on Liquidia: Institutional Vote of Confidence Amidst High Binary Risk

What happened

California State Teachers Retirement System (CalSTRS) significantly increased its stake in Liquidia Corporation, acquiring 5.84 million shares, an 8,055% jump, bringing its total to 5.91 million shares as disclosed in a recent SEC filing. This purchase occurs as Liquidia's stock has surged over 221% in the past year, driven by the FDA approval and commercial launch of YUTREPIA for PAH and PH-ILD, which generated $51.7 million in Q3-25 product sales. However, the company still faces substantial going-concern risk, ongoing litigation with United Therapeutics, and expensive financing covenants, with auditors flagging doubts about its ability to continue as a going concern. The DeepValue master report currently rates LQDA as a 'POTENTIAL SELL,' citing extreme valuation metrics, negative free cash flow, and a highly binary risk profile concentrated on YUTREPIA's success. CalSTRS's massive accumulation may signal long-term institutional confidence, but it does not alter the fundamental challenges or the elevated risk at current price levels.

Implication

CalSTRS's 8,000%+ increase in holdings is notable because large pension funds typically have long investment horizons and may have done extensive due diligence, suggesting they see value beyond current litigation noise. However, their entry could also be part of a broader index or mandate allocation, not necessarily a deep fundamental endorsement. The core thesis remains extremely binary: if YUTREPIA continues to grow and litigation resolves favorably, the stock could still rise, but any adverse ruling or slowdown could trigger sharp declines from a valuation already pricing in substantial success. With P/B ~138x, negative EV/EBITDA, and a DCF-based intrinsic value far below the current price, the margin of safety is minimal. Therefore, while this news may provide short-term sentiment support, it is not a sufficient reason to override the existing cautious stance; investors should monitor upcoming litigation milestones, quarterly YUTREPIA prescriptions, and covenant compliance before committing new capital.

Thesis delta

The large institutional purchase by CalSTRS slightly tempers the bearish view by indicating that sophisticated long-term investors are willing to take on the binary risk. However, it does not change the fundamental assessment that the stock is richly valued with significant legal and financial overhangs. The thesis shifts only marginally from 'POTENTIAL SELL' to 'POTENTIAL SELL with a noteworthy institutional endorsement,' but the core risk profile remains unchanged.